Kurs
+0,63%
Kurs
+0,63%
Open
35,20
High
36,14
Low
34,08
Close
35,24
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
22,9 MNOK
Likviditet
22,9 MNOK
Rel. mcap
2,61%
Antal aktier
656 699
Likviditet under dagen för detta pressmeddelande
Kalender
| Tid* | ||
| 2026-02-25 | 06:30 | Bokslutskommuniké 2025 |
| 2025-11-26 | 00:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | 00:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-22 | N/A | Årsstämma |
| 2025-05-14 | 00:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-26 | 06:30 | Bokslutskommuniké 2024 |
| 2024-11-27 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-21 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2024-05-16 | - | Årsstämma |
| 2024-05-14 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-11-15 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-16 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-12 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2023-05-11 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-11-23 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-16 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-13 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2022-05-12 | - | Årsstämma |
| 2022-03-31 | - | Bokslutskommuniké 2021 |
| 2021-12-22 | - | Extra Bolagsstämma 2021 |
| 2021-11-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-06 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2021-05-05 | - | Årsstämma |
| 2021-04-21 | - | Bokslutskommuniké 2020 |
| 2020-11-17 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-07 | - | Split NYKD 1:5 |
| 2020-07-06 | - | Extra Bolagsstämma |
| 2020-05-12 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-22 | - | Extra Bolagsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2022-05-05 08:00:00
Oslo, Norway, May 5, 2022 - The Board of Directors of Nykode Therapeutics AS
(Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company
dedicated to the discovery and development of vaccines and novel
immunotherapies, hereby calls for the Annual General Meeting to be held at
meeting room FORUM - Building H, Floor 0 in Gaustadalléen 21, Oslo, Norway at
10:00 CET on May 12, 2022.
All documents regarding the Annual General Meeting are available at the
Company's website:
www.nykode.com/investors/corporate-governance/annual-general-meeting/
For further information, please see the Company's website or contact CFO Harald
Gurvin. Please see below for contact details.
Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and eliciting efficacious clinical responses.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus 16 induced malignancies which is in Phase 2
for the treatment of cervical cancer